Sagent Pharmaceuticals, Inc. Announces the Launch of Acetazolamide for Injection, USP
11/13/2012 8:14:19 AM
SCHAUMBURG, Ill., Nov. 13, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Acetazolamide for Injection, USP, the generic form of the carbonic anhydrase inhibitor Diamox®, in a latex-free vial presentation. According to IMS data for the 12 months ending September 2012, the US market for Acetazolamide for Injection, USP approximated $9.5 million. As with all products in Sagent's portfolio, Acetazolamide features the company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.
comments powered by